Sumi  Shrishrimal net worth and biography

Sumi Shrishrimal Biography and Net Worth

SVP of DexCom

Sumi Shrishrimal currently serves as the Chief Risk Officer for Dexcom.

In this role, Sumi is responsible for Dexcom’s Enterprise Risk Management Program, including identifying, evaluating, and managing Dexcom’s risks. Sumi is responsible for Dexcom’s Global Compliance and Privacy Program ensuring compliance with applicable Healthcare and Privacy laws and regulations. She is also responsible for the Internal Audit Department managing Sarbanes-Oxley compliance, operational and compliance audits, and other fraud and special investigations.

Prior to Dexcom, Sumi served as the Vice President of Internal Audit at NuVasive where she was responsible for Sarbanes-Oxley compliance; financial, information technology and compliance audits; operational audits; fraud investigations; and other special projects. Over the course of her career, Sumi has held multiple leadership positions in internal audit and accounting within the medical device, education, and financial services industries. Sumi started her career with PricewaterhouseCoopers where she consulted on a wide range of projects in the Assurance Business Advisory Services and the Transaction Services groups.

Sumi is a Certified Public Accountant in California and a Certified Information Systems Auditor. She holds a Bachelor’s in Accounting and Information Systems from the University of Mumbai.

How do I contact Sumi Shrishrimal?

The corporate mailing address for Ms. Shrishrimal and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Sumi Shrishrimal's contact information.

Has Sumi Shrishrimal been buying or selling shares of DexCom?

Sumi Shrishrimal has not been actively trading shares of DexCom in the last ninety days. Most recently, Sumi Shrishrimal sold 400 shares of the business's stock in a transaction on Friday, July 16th. The shares were sold at an average price of $450.00, for a transaction totalling $180,000.00. Learn More on Sumi Shrishrimal's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 46 times. They sold a total of 282,221 shares worth more than $31,702,358.23. The most recent insider tranaction occured on December, 1st when EVP Michael Jon Brown sold 3,612 shares worth more than $413,790.72. Insiders at DexCom own 0.4% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 12/1/2023.

Sumi Shrishrimal Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/16/2021Sell400$450.00$180,000.00View SEC Filing Icon  
6/11/2021Sell400$401.09$160,436.00View SEC Filing Icon  
5/25/2021Sell1,461$354.79$518,348.19View SEC Filing Icon  
See Full Table

Sumi Shrishrimal Buying and Selling Activity at DexCom

This chart shows Sumi Shrishrimal's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $118.64
Low: $116.38
High: $119.06

50 Day Range

MA: $95.30
Low: $75.49
High: $118.24

2 Week Range

Now: $118.64
Low: $74.75
High: $139.55


940,396 shs

Average Volume

3,369,650 shs

Market Capitalization

$45.84 billion

P/E Ratio


Dividend Yield